Our IsoClear™ Platform
Enabling the rapid development of simpler, clearer cancer diagnostics
Our IsoClear platform measures structural differences in proteins to determine if biomarkers originated in cancer cells. This simple yet robust platform enables the efficient development of a portfolio of affordable blood tests that add clarity to cancer diagnostics.
Our first test: IsoPSA
Reduces unnecessary prostate biopsies by up to 55%1
With high sensitivity and a specificity two to three times that of traditional PSA tests, 2-4 IsoPSA clarifies in whom aggressive cancer may reside—and in whom it may not.
1 Scovell J, et al., Urol. Pract 2022.
2 Klein EA, et al., Eur Urol. 2017.
3 Stovsky M, et al., J Urol. 2019.
4 Podium presentation, AUA-NCS 2021.